<DOC>
	<DOCNO>NCT00576628</DOCNO>
	<brief_summary>This single arm study ass efficacy , safety tolerability subcutaneous C.E.R.A . correction anemia maintenance hemoglobin level patient chronic kidney disease dialysis treat ESA . Eligible patient receive C.E.R.A . monthly subcutaneous injection , dependent body weight ( recommend start dose 1.2 micrograms/kg ) . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Subcutaneous C.E.R.A . Treatment Anemia Pre-Dialysis Patients .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia , need dialysis expect next 3 month ; adequate iron status . previous epoetin therapy within 12 week prior treatment ; transfusion red blood cell 2 month prior screen ; significant acute chronic bleed overt gastrointestinal bleeding ; hemolysis ; folic acid vitamin B 12 deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>